Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398430 | 1.00 | HRH3 (0.38) | HRH3PIK3CDCYP3A4HDAC1YTHDC1 | |
| SCHEMBL2398432 | 1.00 | HRH3 (0.38) | HRH3PIK3CDCYP3A4HDAC1YTHDC1 | |
| SCHEMBL2395856 | 0.82 | HRH3 (0.39) | HRH3PIK3CDCYP3A4HDAC1CNR2 | |
| SCHEMBL2395848 | 0.82 | HRH3 (0.39) | HRH3PIK3CDCYP3A4HDAC1CNR2 | |
| SCHEMBL2673423 | 0.82 | PIK3CD (0.43) | HRH3PIK3CDHDAC1YTHDC1 | |
| SCHEMBL2674294 | 0.81 | ATR (0.37) | HRH3PIK3CDHDAC1 | |
| SCHEMBL2101166 | 0.80 | PIK3CD (0.45) | PIK3CDHDAC1 | |
| SCHEMBL2394343 | 0.80 | HDAC1 (0.39) | PIK3CDHDAC1YTHDC1 | |
| SCHEMBL9937266 | 0.80 | HDAC1 (0.37) | HRH3PIK3CDCYP3A4HDAC1YTHDC1 | |
| SCHEMBL9936995 | 0.80 | HDAC1 (0.40) | HRH3PIK3CDCYP3A4HDAC1YTHDC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2215090-B1 | PURINE DERIVATIVES USEFUL AS PI3 KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-03-04 | — | — | EP | disclosed |
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230464-A1 | PURINE DERIVATIVES USEFUL AS P13 KINASE INHIBITORS | PIK3CA, PIK3CD, PI4KA | HRH3 2781/4885PIK3CD 2/4885CYP3A4 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.